Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.
It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
Inadequate use of masks or respirators put health care workers at risk of 2009 H1N1 infection during the earliest stages of the 2009 pandemic in the U.S., according to a study published in the December issue of Infection Control and Hospital Epidemiology, the journal of the Society of Healthcare Epidemiology of America.
A team of researchers from the Johns Hopkins Children's Center, Vanderbilt University and elsewhere have demonstrated that high blood pressure and anemia together put children with sickle cell disease (SCD) at serious danger for symptomless or so-called "silent" strokes, although either condition alone also signaled high risk.
The National Institutes of Health (NIH) has awarded $3.2 million to a team of preeminent engineering, chemistry, and biology researchers to develop a highly efficient system of generating nucleic acid molecules, called aptamers.
According to the Centers for Disease Control and Prevention (CDC), three cases of a new flu virus have been confirmed. These originated in pigs but apparently spread from person to person, in three Iowa children.
Inovio Pharmaceuticals, Inc., which is advancing synthetic vaccines to fight cancers and infectious diseases, announced today that a single intradermal (ID) electroporation boost of its SynCon avian influenza vaccine generated HAI titers against six different, unmatched strains of H5N1 - a distinct new clinical achievement on the global research community's path to develop universal influenza vaccines.
A hand and respiratory hygiene program including frequent use of alcohol-based hand sanitizer helps reduce illness caused by influenza A and missed school days in elementary school children, reports a study in the November issue of The Pediatric Infectious Disease Journal. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today its unaudited third quarter financial results for the period ended September 30, 2011.
A natural lipid in the fluid lining the lungs inhibits influenza infections in both cell cultures and mouse models, according to researchers at National Jewish Health. These findings, combined with previous studies demonstrating effectiveness against respiratory syncytial virus, suggest that the molecule, known as POPG, may have broad antiviral activity.
SEEK, a leading UK privately-owned drug-discovery group, today announced encouraging results following the successful completion of its Universal Flu Vaccine Phase II challenge study.
During the 2009 H1N1 influenza pandemic, many previously healthy children became critically ill, developing severe pneumonia and respiratory failure, sometimes fatal. The largest nationwide investigation to date of influenza in critically ill children, led by Children's Hospital Boston, found one key risk factor: Simultaneous infection with methicillin-resistant Staphylococcus aureus (MRSA) increased the risk for flu-related mortality 8-fold among previously healthy children.
Financial strain and competing priorities at home may contribute to the greater number of hospital readmissions of children with asthma from single-parent homes compared to dual-parent households, according to a new study presented at the American College of Allergy, Asthma and Immunology Annual Meeting in Boston, Nov. 3-8.
Guided by insights into how mice recover after H1N1 flu, researchers at Harvard Medical School and Brigham and Women's Hospital, together with researchers at A*STAR of Singapore, have cloned three distinct stem cells from the human airways and demonstrated that one of these cells can form into the lung's alveoli air sac tissue.
According to a report published online October 25 in The Lancet Infectious Diseases there are gaps in the evidence for the effectiveness of licensed influenza vaccines in the United States. Individuals who are at risk for medical complications or people who are aged 65 years or older are especially affected by the gaps, the researchers write.
The pivotal pediatric clinical study compared Q/LAIV to two trivalent formulations of MedImmune's licensed seasonal influenza vaccine, FluMist (Influenza Vaccine Live, Intranasal) and met its primary endpoint.
Sanofi Pasteur, the vaccines division of Sanofi, announced today the results of a new study evaluating the immunogenicity and safety of an investigational quadrivalent inactivated influenza vaccine (QIV) among adults 65 years of age and older.
Romark Laboratories announced that results of a large Phase 2B-3 US clinical trial of its new flu drug, NT-300 (nitazoxanide), will be presented as an oral late-breaking communication at the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA) being held in Boston, October 20-23, 2011.
NanoViricides, Inc. announced that its President, Dr. Anil Diwan, has completed the programmed sale of the NanoViricides stock that he had obtained as a founder.
A unique and innovative analysis of how social media can affect the spread of a disease has been designed and implemented by a scientist at Penn State University studying attitudes toward the H1N1 vaccine. Marcel Salath-, an assistant professor of biology, studied how users of Twitter -- a popular microblogging and social-networking service -- expressed their sentiments about a new vaccine.
Building on the success of Louisville's response to the 2009 H1N1 influenza pandemic, Ruth Carrico, PhD, plans to use a $250,000 one-year cooperative agreement from the Centers for Disease Control and Prevention (CDC) to create an emergency countermeasure staffing plan that utilizes nursing, pharmacy and public health students.
CEL-SCI Corporation announced today that it has closed its previously announced registered direct offering for the sale of (i) 13,333,334 shares of its common stock at a price per share of $0.30 and (ii) warrants to purchase up to 12,000,000 shares of CEL-SCI Corporation's common stock at a purchase price of $0.40. The warrants may be exercised at any time prior to October 6, 2014.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.